Epstein Secrets

at current levels. The fundamental bull case for Health rests on the strong pipeline of new products for

en considered and distributed in Japan by Merrill Lynch (Japan), a registered securities dealer under the

ervices 1,720 Tax credit for orphan drug research Health 100 Exclusion & deferral of policyholder income e

s is a regular issuer of traded financial instru Lynch, through business units other than Bo th, and rea

ncrease penetration of higher margin offerings 48 Health: Not Tremendously Prescriptive 51 Vision 2030 a s

ubai Financial Services Authority (DFSA); Merrill Lynch (Spain): Merrill Lynch Capital Markets Espana, S.

-12 1% 78 3.0% -13 % 33 -0.4% 6 68% -0./% SXDP (Health) 3.0% -08% 1% 8.7% 0.9% 9 2% 115 2.5% -12 3% 40

ynch | the FCA and the PRA) by RA - details about Lynch (Japan), a registered securities dea investors a

3% -] 2% 74 3.1% = 2% 3.2 -0.4% 0 54% 0.9% SXDP (Health) 3.1% -0.6% 2% 86% 0.9% -/ 2% 115 24% -14 2% 4]

ea issued and distributed in Tai investors and/or accredited investors Company hee er under the wan by Merri ch as defi A Australia) and poration ILynch by MLP iliates d hority; Lynch International (DIFC Branch), regulated by t ores; Merrill Lynch (Brazi bia Company, regu n and is d PRA) by MLI (UK)